Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy

References

• Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant 2011;46:174–191.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34 + cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967–972.
   PubMed Web of Science ®Google Scholar
• Bender JG, To LB, Williams S, et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992;1:329–341.
   PubMedGoogle Scholar
• Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 + cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360–1377.
   PubMed Web of Science ®Google Scholar
• Shpall EJ, Champlin R, Glaspy JA. Effect of CD34 + peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4:84–92.
   PubMedGoogle Scholar
• To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011;118:4530–4540.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Lemoli M. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012;52:906–914.
   PubMed Web of Science ®Google Scholar
• Ford CD, Green W, Warenski S, et al. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004;33:901–905.
   PubMed Web of Science ®Google Scholar
• Berger MG, Berger J, Richard C, et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progentiors to fludarabine suggest impaired bone marrow niche and HP mobilization. Leukemia 2008;22:2131–2134.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998;4:311–316.
   PubMed Web of Science ®Google Scholar
• Keane C, Gibbs, S, Seymour JF, et al. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematol Oncol 2006;24:159–163.
   PubMed Web of Science ®Google Scholar
• Hill BT, Rybicki L, Smith S, et al. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk Lymphoma 2011;52:986–993.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Cortes J, et al. Outcome with the Hyper-CVAD regimen in lymphoblastic lymphoma. Blood 2004; 104:1624–1630.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remission after treatment of newly diagnosed aggressive mantle- cell lymphoma with rituimab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:1062–1073.
   PubMed Web of Science ®Google Scholar
• Dreyling M. Hyper-CVAD in mantle-cell lymphoma: Really “hyper” or just hype?Leuk Lymphoma 2008;49:1017–1018.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmayer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef I, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39–47.
   PubMed Web of Science ®Google Scholar
• Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011;51:2175–2182.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64–69.
   PubMed Web of Science ®Google Scholar
• Abhyankar S, Dejarnette S, Aljitwi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012;47:483–487.
   PubMed Web of Science ®Google Scholar
• Xia C, Zhong XB, Dhokal B, et al. Plerixafor overcomes the adverse effect of diabetes on hematopoietic progenitor cell mobilization. Biol Blood Marrow Transplant 2013;19(Suppl. 2):S182–S183, Abstract 158.
   Google Scholar
• Malard F, Kroger N, Gabriel IH, et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012;18:314–317.
   PubMed Web of Science ®Google Scholar
• Micromedex® 2.0 Healthcare Series/Redbook Online® [Intranet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Available from: www.micromedex.com [accessed 24 January 2013].
   Google Scholar